

10/573584

PATENT APPLICATION

27 MAR 2006
T AND TRADEMARK OFFICE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:)
GOLZ et al) Group Art No. TBA
Serial No: TBA) Examiner: TBA
Filed: Herewith) Docket No. 004974.01115

For: DIAGNOSTICS AND THERAPEUTICS
FOR DISEASES ASSOCIATED WITH
ARGINYL AMINOPEPTIDASE RNPEP (RNPEP)

INFORMATION DISCLOSURE STATEMENT

U.S. Patent and Trademark Office
Customer Service Window, Mail Stop New Application
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

Pursuant to 37 C.F.R. §1.56 and in compliance with 37 C.F.R. §1.97, Applicants submit herewith Form PTO-1449 identifying information for consideration by the Examiner.

It is believed that no fee is required to ensure consideration of the cited references by the Examiner. However, if a fee is deemed necessary, the Commissioner is authorized to charge our Deposit Account No. 19-0733.

Respectfully submitted,

BANNER & WITCOFF, LTD.

Date: March 27, 2006

By: Lia M. Hennebinger

Lisa M. Hemmendinger
Registration No. 42,653

Banner & Witcoff, Ltd.
Customer No. 22907
LMH:sdm

U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No. 004974.01115		Serial No. Q0157584 TBA			
INFORMATION DISCLOSURE CITATION Sheet 1 of 1		Applicant(s): GOLZ et al					
		Filing Date: March 27, 2006		Group: TBA			
U.S. PATENT DOCUMENTS							
Examiner Initial	Patent No.	Date	Name	Class	Subclass		
FOREIGN PATENT DOCUMENTS							
Examiner Initial	Document No.	Date	Country	Class	Subclass	Translation	
						YES	NO
	WO 01/83782 A	08 November 2001	PCT				
	WO 01/36605 A	25 May 2001	PCT				
	WO 01/53455 A	26 July 2001	PCT				
	WO 2005/031358	7 April 2005	PCT				
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)							
EXAMINER				DATE CONSIDERED			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.